LEGN - Legend Biotech Corporation - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

20.59B

Cash

1.302B

Avg Qtr Burn

-59.64M

Short % of Float

6.93%

Insider Ownership

1.32%

Institutional Own.

49.21%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CARVYKTI (cilta-cel) Details Multiple myeloma, Blood cancer, Cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CARVYKTI (cilta-cel) (ciltacabtagene autoleucel) Details Cancer, Multiple myeloma, Blood cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Daratumumab + Bortezomib + Lenalidomide + Dexamethasone (DVRd) Details Multiple myeloma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LB2102 Details Cancer, Small cell lung cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LB1901 (antiCD4) Details Cancer, T-cell lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.